Financial News Now - Your source for financial news that matters most

This Cutting-Edge Psychedelics and Cannabis Company Is Positioned to Dominate the Global Mental Health Market

Broadcast Bob
May 18, 2021

1

Mental disorders have risen to rank among the most devastating and costly medical challenges in the United States and the world. Estimates are that 300 million people globally suffer the debilitating effects of PTSD, chronic depression/anxiety, and the related impact of opioid addictions.

2

Clinical trials have already shown significant promise for treating these disorders with cannabinoids and psychedelic compounds. Until recently these compounds have been vilified as illegal recreational drugs. Now, clinicians and medical researchers are unlocking a vast array of therapeutic potentials for treating some of the most challenging medical issues. Allied is contributing to this research with its own clinical trials treating PTSD, depression/anxiety disorders and opioid addiction.

3

On the heels of new therapeutic breakthroughs, the FDA is now fast-tracking approval processes for the psychedelic compound psilocybin. This fast-track approval process could lead to therapeutic approvals this year, which can be added to already advanced treatments being evaluated for cannabinoid compounds. Investors are moving aggressively in anticipation of a stream of approvals that could begin as early as this year.

4

Though this market remains in its infancy, early gainers have posted ten- to thirty-times growth from this emerging trend. This is a rapidly growing, multi-billion-dollar market in the making — one of the very few that you will see in your lifetime.

5

Allied Corp. (OTCQB: ALID) is unique in the world in that it has focused diligently on building the end-to-end capability to deliver pharmaceutical-grade cannabinoids and psychedelic compounds (as legislation allows) at a scale that meets all current global growth projections. The company is now fully structured to become one of the largest, if not the largest, supplier of pharmaceutical-grade cannabinoids and psychedelic compounds to the world. Its capabilities allow total control, end to end, of the supply chain. Nobody else does what they do to provide scalable, high-quality, and dependable compounds to a market projected to approach $60 billion this decade!

I want to subscribe today to Financial News Now and receive up-to-date information in my inbox. Sign me up!
Broadcast Bob
Bob sees all and knows all.
ABOUT US
MARKET DATA
WORLD MARKETS
FOLLOW US
SUBSCRIBE!
©2022 ALL RIGHT RESERVED - FINANCIAL-NEWS-NOW
menu